xiv New Patents

8601105

PHARMACEUTICAL COMPOSITION FOR

COMBINATION THERAPY OF HORMONE DEPENDENT

CANCERS

Fernand LABRIE, Alain BELANGER, Andr@ DUPONT, 2735 boul Li@geois, St-Foy, Quebec G 1W I Z9, Canada

A method of treating sex steroid dependent cancers in a warm-blooded animal which com- prises administering a pharmaceutically effective amount of an antiandrogen and/or an anti- estrogen and/or at least one inhibitor of sex steroid biosynthesis to the animal whose hor- mone output of the testes or ovaries, respec- tively, is blocked, with the proviso that the method of treating prostate cancer comprises ad- ministering pharmaceutically effective amounts of an antiandrogen and at least one inhibitor of sex steroid biosynthesis and with the further pro- viso that, if antiestrogen is used in treating breast cancer it is used in association with an anti- androgen and/or at least one inhibitor of sex steroid biosynthesis. The invention further relates to kits containing pharmaceutical com- positions containing the active ingredients to be used in the novel combination therapy.

8601108

NEW PHARMACEUTICAL COMPOSITION

Joseph AGIUS, John MORLEY, Wolf-Dieter ROTH, Karl-Heinz HAHN, Gartenstrasse 67, CH-4132 Muttenz, Switzerland assigned to SANDOZ AG

The composition contains: a) ketotiphene and b) xanthine having an anti-asthmatic activity, par- ticularly theophylline in the form of a stable combination appropriate for the treatment, par- ticularly for the preventive or prophylactic treat- ment of asthma or for reducing a respiratory tract resistance in particular during the preven- tive or prophilactic treatment of asthma.

8601405

PHARMACEUTICAL PREPARATION AND

PRODUCTION PROCESS THEREFOR

Walter BURGHART, Kurt BURGHART, Sal- mgasse 4, A-1030 Wien, Austria assigned to KUHLEMANN & CO,

The pharmaceutical preparation contains nifedipine as active agent and is conditioned as an aerosol by using a propelling gas or a spray. When using propelling gases, the preparation contains preferably from 2 to 5 % by weight of nifedipine, 25 to 40% by weight of polyethylene- glycol, 40 to 259/00 by weight of ethanol and 30 to 409/0 by weight, preferably 35% by weight of the propulsion agent, whereas in case of a spray, the preparation appropriately contains 19 mg of nifedipine, 70 to 100 mg of polyethylene-glycol, particularly a mixture of polyethylene-glycol 600 and polyethylene-glycol 400 in a ratio from 5:4 to 4:5, 30 to 40 mg of ethanol, 5 to 20 mg of water and optionally 2 to 5 mg of saccharine and 1 to 3 mg of flavouring agent like peppermint oil.

8601803

CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND

PHARMACEUTICAL COMPOSITIONS CONTAINING

THEM

David Roy ANDREWS, Federico Carlos Arejola GAETA assigned to SCHERING CORPORATION

Novel carboxyalkyldipeptides, their prepara- tion and pharmaceutical compositions con- taining them. The novel dipeptides are represented by general formula (I), where A is selected from formula (II), with n, p and q being specified values from 0 to 2, B is -)ADJ)BD- )ADL)BD-)ADM)BD-; D is formula (III), E is -NH-, -O-, -S-, or -CH)2(-; G is formula (IV) or -SO)2(-; J is - ( c n ) 2 0 ) s ( - or -((CH)2())t(-W- ; where L is chemical bond, specified alkyl, aryl or heterocyclic moieties, M is - (CH)20)u( - or - ((CH)2())t(-X-(CH)20)v()- where n and v are 0-5 and X is -NR(9)-, -O-, -S-, formula (V) or formula (VI), R(1 ) and R(2) are hydrogen, lower alkyl or lower acyl; R(3) is hydrogen, lower alkyl, haloloweralkyl, phenylloweralkyl,